此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

IL-13 通路对特应性皮炎患者和健康志愿者疼痛和瘙痒敏感性的作用 (IL-13)

2026年11月5日 更新者:Silvia Lo Vecchio、Aalborg University

Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.

研究概览

详细说明

Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the interleukin-13 is involved in inflammation and itch in atopic dermatitis by increasing the neuronal sensitivity to pruritogens. However, the physiological mechanisms by which IL-13 increases the itch sensitivity are unclear. The aim of this project is to use, for the first time in humans, the monoclonal antibody Lebrikizumab that inhibits IL-13 with high affinity as a novel experimental tool to modulate the IL-13 pathway and evaluate its role in the transmission and processing of itch and pain.

研究类型

介入性

注册 (估计的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Silvia Lo Vecchio
  • 电话号码:21397785
  • 邮箱:slv@hst.aau.dk

学习地点

    • Aalborg
      • Gistrup、Aalborg、丹麦、9260
        • 招聘中
        • Aalborg University
        • 接触:
          • Silvia Lo Vecchio, PhD
          • 电话号码:21397785
          • 邮箱:slv@hst.aau.dk
        • 接触:
        • 首席研究员:
          • Silvia Lo Vecchio, PhD
        • 副研究员:
          • Botilla Markussen
      • Gistrup、Aalborg、丹麦、9260
        • 主动,不招人
        • CNAP
    • Denmark
      • Aalborg、Denmark、丹麦、9260
        • 尚未招聘
        • Aalborg University
        • 接触:
          • Silvia Lo Vecchio

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Healthy men and women
  • 18-60 years

Exclusion Criteria:

  • Pregnancy or lactation
  • Drug addiction defined as any use of cannabis, opioids, or other drugs
  • Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)
  • Moles, wounds, scars, or tattoos in the area to be treated or tested
  • Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).
  • Use of systemic and topical corticosteroids
  • Consumption of alcohol or painkillers 24 hours before the study days and between these
  • Acute or chronic pain
  • Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
  • Lack of ability to cooperate

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Lebrikizumab

The initial doses will be subcutaneous Lebrikizumab 500 mg (two 250 mg injections) at both week 0 (baseline) and week 2, followed by 250 mg administered subcutaneously at week 4.

Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.

A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.

A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Superficial blood perfusion
大体时间:Baseline

Superficial blood perfusion (SBP) is measured by a Speckle contrast imager

Baseline
Mechanically evoked itch (MEI)
大体时间:Baseline

MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).

Baseline
Measuring itch by computerized Visual Analog Scale Scoring
大体时间:1 minute after every itch induction

The subjects will be asked to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no itch" and 100 indicates "worst itch imaginable".

1 minute after every itch induction
Measuring pain by computerized Visual Analog Scale Scoring
大体时间:1 minute after every itch induction

The subjects will be asked to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable".

1 minute after every itch induction
Superficial blood perfusion
大体时间:10 minute after every itch induction

Superficial blood perfusion (SBP) is measured by a Speckle contrast imager

10 minute after every itch induction
Wheal reaction
大体时间:10 minute after every itch induction

Wheal reaction measurement will be conducted immediately after the removal of pruritogens by measuring the longest diameter with a ruler.

10 minute after every itch induction
Average pruritis and pain numerical rating scale (NRS)
大体时间:Baseline

The subject will be asked to retrospectively rate the average and worst itch/pain on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain)experience they had during the last 7 days.

Baseline
Skin peak pain numerical rating scale (SPP-NRS)
大体时间:Baseline

According to the SPP-NRS, the subject will be asked about "worst skin pain" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain)

Baseline
Peak pruritus numerical rating scale (PP-NRS)
大体时间:Baseline

The subject will be asked about the "worst itch" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no itch and 10 = worst imaginable itch)

Baseline
Mechanically evoked itch (MEI)
大体时间:10 minutes after every itch induction

MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).

10 minutes after every itch induction

次要结果测量

结果测量
措施说明
大体时间
Mechanical Pain Thresholds (MPT)
大体时间:Baseline

This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN.

Baseline
Mechanical Pain Sensitivity (MPS)
大体时间:Baseline

This test is conducted with the same pinprick set used to test the MPT.

Baseline
Pressure Pain Thresholds (PPT)
大体时间:Baseline

Pressure will be applied by a handheld electronic pressure algometer (Somedic AB, Stockholm, Sweden) on to the supinator muscle on the left forearm.

Baseline
Cold Detection Thresholds (CDT)
大体时间:Baseliene

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

Baseliene
Warm Detection Thresholds (WDT)
大体时间:Baseline

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testingdevice

Baseline
Cold Pain Thresholds (CPT)
大体时间:Baseline

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

Baseline
Heat Pain Thresholds (HPT)
大体时间:Baseline

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

Baseline
Pain to Supra-threshold Heat Stimuli (STHS)
大体时间:Baseline

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年1月6日

初级完成 (实际的)

2025年12月31日

研究完成 (估计的)

2026年12月31日

研究注册日期

首次提交

2024年7月10日

首先提交符合 QC 标准的

2024年7月10日

首次发布 (实际的)

2024年7月16日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅